Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model-Reference-Cited by-同舟云学术

Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model

Published:2020-11-02 Issue:5 Volume:21 Page:1011-1016
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Dos Santos Jéssica Barreto Ribeiro¹²,da Silva Michael Ruberson Ribeiro¹²^ORCID,Almeida Alessandra Maciel²³,Acurcio Francisco De Assis²⁴^ORCID,Alvares-Teodoro Juliana²^ORCID

Affiliation:

1. Health Assessment, Technology, and Economy Group, Center for Exact, Natural and Health Sciences, Federal University of Espírito Santo, Alegre, Espírito Santo, Brazil

2. Department of Social Pharmacy, College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

3. Faculty of Medical Sciences of Minas Gerais, Belo Horizonte, Minas Gerais, Brasil

4. Department of Social and Preventive Medicine, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

Funder

the National Council for Scientific and Technological Development - CNPq

Minas Gerais Research Support Foundation - FAPEMIG

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2021.1840980

Reference27 articles.

1. Rheumatoid arthritis

2. World Health Organization (WHO) [Internet]. Geneve; 2020. Available from: https://www.who.int/chp/topics/rheumatic/en/

3. Brazil. Ministry of Health. Approves the clinical protocol and therapeutic guidelines for rheumatoid arthritis and juvenile idiopathic arthritis [Internet]. Brasília; 2020. Available from: https://www.saude.gov.br/images/pdf/2020/marco/20/Portaria-Conjunta-PCDT-Artrite-Reumatoide-e-AIJ-20.03.2020.pdf

4. Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1

5. Impacto da artrite reumatoide no sistema público de saúde em Santa Catarina, Brasil: análise descritiva e de tendência temporal de 1996 a 2009

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States;Expert Review of Pharmacoeconomics & Outcomes Research;2022-09-06

2. Health-Related Quality of Life in Psoriatic Arthritis: Findings and Implications;Value in Health Regional Issues;2021-12

3. Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept;BioMed Research International;2021-11-28

4. Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model;Expert Review of Pharmacoeconomics & Outcomes Research;2021-02-09